Future Prospects for Bridge Enhanced ACL Repair in ACL Injury Treatment
DOI:
https://doi.org/10.54097/2kvxr917Keywords:
BEAR; anterior cruciate ligament; collagen scaffold; ligamentization.Abstract
Anterior cruciate ligament (ACL) is one of the four most important ligaments in human knee, and ACL tears are one of the most commonly seen injuries among common ligamentous knee injuries. Severe ACL tears usually require surgical treatment for complete recovery. In the past decades, ACL reconstruction (ACLR) has been the gold standard by its high success rate and easiness on surgical application. However, ACLR sacrifices native ligament tissue and may lead to donor-site morbidity and delayed neuromuscular recovery. The new Bridge-Enhanced ACL Repair (BEAR) technique introduces a biologically augmented approach that keeps the patient’s native ligament tissue and proprioceptive fibers while restoring ligament integrity. Histological analyses have proven ligament function regeneration sign on BEAR treated patients. In randomized controlled and prospective cohort studies, BEAR treated patients show better IKDC and KOOS improvements compared to patients treated with traditional ACLR. Clinical reports further validate BEAR’s potential to reduce postoperative complications and enhance neuromuscular function. This review aims to synthesize the biological rationale, operative evolution, clinical effectiveness, and remaining challenges of BEAR in contemporary ACL care.
Downloads
References
[1] Kotsifaki R, Korakakis V, King E, et al. Aspetar clinical practice guideline on rehabilitation after anterior cruciate ligament reconstruction. British Journal of Sports Medicine, 2023, 57(9): 500-514.
[2] Barth KA, Lawton CD, Touhey DC, et al. The negative impact of anterior cruciate ligament reconstruction in professional male footballers. Knee, 2019, 26(1): 142-148.
[3] Brinlee AW, Dickenson SB, Hunter-Giordano A, et al. ACL reconstruction rehabilitation Clinical data, biologic healing, and criterion-based milestones to inform a return-to-sport guideline. Sports Health, 2022, 14(5): 770-778.
[4] Barnes DA, Badger GJ, Yen YM, et al. Quantitative MRI biomarkers to predict risk of reinjury within 2 years after bridge-enhanced ACL restoration. American Journal of Sports Medicine, 2023, 51(2): 413-421.
[5] Malahias MA, Chytas D, Nakamura K, et al. A narrative review of four different new techniques in primary anterior cruciate ligament repair “Back to the future” or another trend? Sports Medicine Open, 2018, 4(37): 1-12.
[6] McMillan S, Putra J, Patel S, et al. Histological analysis of bridge-enhanced ACL restoration tissue in ligament retears. Orthopaedic Journal of Sports Medicine, 2025, 13(4): 23259671251331046.
[7] Szukics PF, Fliegel BE, Baker WF, et al. An isolated midsubstance ACL tear repaired with the BEAR system. Video Journal of Sports Medicine, 2024, 4(1): 26350254231203732.
[8] Shah AK, Rizy ME, Neijna AG, et al. A preliminary study of post-market bridge-enhanced ACL restoration suggests non-inferior short-term outcomes and low complications. HSS Journal, 2024, 1(1): 1-10.
[9] Shah AK, Neijna AG, Retzky JS, et al. Indications, techniques, and outcomes of bridge-enhanced ACL restoration. Current Reviews in Musculoskeletal Medicine, 2025, 18(1): 140-148.
[10] Murray MM, Fleming BC, Badger GJ, et al. Bridge-enhanced anterior cruciate ligament repair is not inferior to autograft anterior cruciate ligament reconstruction at 2 years Results of a prospective randomized clinical trial. American Journal of Sports Medicine, 2020, 48(6): 1305-1315.
[11] Khan AU, Aziz R, Reen M, et al. The first case of bridge-enhanced anterior cruciate ligament repair procedure in Mississippi. Cureus, 2023, 15(8): e44218.
[12] Tjoumakaris FP, Herz-Brown AL, Legath-Bowers A, et al. Complications in brief Anterior cruciate ligament reconstruction. Clinical Orthopaedics and Related Research, 2012, 470(2): 630-636.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Highlights in Science, Engineering and Technology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







